3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
2
Head & Neck
1
Gynecologic
1
Conditions
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Breast Neoplasms
1
Breast Diseases
1
Interventions
Paclitaxel
77
pembrolizumab
65
Carboplatin
57
Bevacizumab
57
Specimen Handling
49
Magnetic Resonance Spectroscopy
40
Cisplatin
35
olaparib
31
Gemcitabine
27
liposomal doxorubicin
25
Biopsy
22
Taxes
19
Cyclophosphamide
18
Topotecan
17
Nivolumab
17
Doxorubicin
16
Immunoglobulin G
15
niraparib
14
Letrozole
14
Disulfides
14
lenvatinib
13
fludarabine
13
Surveys and Questionnaires
12
Drug Therapy
12
Radiotherapy
11
Platinum
11
atezolizumab
10
abemaciclib
10
durvalumab
9
Fulvestrant
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
STX-478
×
Gynecologic
×
90 days
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled